3-V Biosciences

3-V Biosciences is a privately held biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. 3-V Biosciences was founded by The Column Group (TCG) and Kleiner Perkins Caulfield & Byers (KPCB) in March 2007. In April 2007, the original laboratory was opened in Zürich, Switzerland in close proximity to the company’s founders at the ETH (Swiss Federal Institute of Technology) and the University of Zürich. Host pathway screening began in November 2007 and continues today.
Type
Private
HQ
Menlo Park, US
Founded
2007
Employees
16 (est)-11%
3-V Biosciences was founded in 2007 and is headquartered in Menlo Park, US

Key People at 3-V Biosciences

Stephen R. Brady

Stephen R. Brady

Chief Business Officer
Merdad Parsey

Merdad Parsey

Chief Executive Officer & BOD
Sara Nayeem

Sara Nayeem

Investor
Richard Klausner

Richard Klausner

Former Director
Douglas I Buckley,

Douglas I Buckley,

Vice President, Biology
George Kemble

George Kemble

Chief Scientific Officer

3-V Biosciences Locations

Menlo Park, US

3-V Biosciences Metrics

3-V Biosciences Summary

Founding Date

2007

Total Funding

$129 M

Latest funding size

$14.3 M

Time since last funding

over 1 year

Investors

3-V Biosciences's latest funding round of $14.3 M was in March 2015. In total, 3-V Biosciences has raised $129 M.
10% of current employees of 3-V Biosciences are female and 90% are male.

3-V Biosciences News

3-V Biosciences Company Life

You may also be interested in